Peter A Mead1, Joseph E Safdieh2, Philip Nizza3, Sejean Tuma, Kent A Sepkowitz4. 1. Infectious Disease Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA. Electronic address: meadp@mskcc.org. 2. Department of Neurology and Neuroscience, Weill Cornell Medical College, New York, NY, USA. 3. Eastern Infectious Diseases Associates, East Setauket, NY, USA. 4. Infectious Disease Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Abstract
OBJECTIVES: Ommaya reservoirs (OmR) are used in the treatment of cancer yet risk factors and outcome of infection are not well characterized. We therefore examined our experience with this device. METHODS: Using administrative databases, we identified all patients with OmR in situ between 1993 and 2008 at Memorial Sloan-Kettering Cancer Center. Charts were reviewed for laboratory, demographic, and clinical information. RESULTS: During the study period, 616 patients with OmRs received care at MSKCC comprising 462,467 Ommaya-days. 34 patients with OmR infection were identified (5.5% of patients, 0.74 infections per 10,000 Ommaya-days). 32% of infections occurred within 30 days of OmR placement. Most (74%) OmR infections occurring after 30 days post-placement were associated with OmR access in the preceding 30 days. Recovered organisms included coagulase-negative staphylococci (56%) and Propionibacterium acnes (24%). 70% of patients had fever and/or headache and 69% had cerebrospinal fluid pleocytosis. 50% of patients had the reservoir removed during treatment of the infection. CONCLUSIONS: OmR infection occurs in one of every 20 persons with the device. A third of the infections appear related to OmR placement while the remainder may occur at any time and usually are associated with recent reservoir access. Treatment often includes device removal.
OBJECTIVES: Ommaya reservoirs (OmR) are used in the treatment of cancer yet risk factors and outcome of infection are not well characterized. We therefore examined our experience with this device. METHODS: Using administrative databases, we identified all patients with OmR in situ between 1993 and 2008 at Memorial Sloan-Kettering Cancer Center. Charts were reviewed for laboratory, demographic, and clinical information. RESULTS: During the study period, 616 patients with OmRs received care at MSKCC comprising 462,467 Ommaya-days. 34 patients with OmR infection were identified (5.5% of patients, 0.74 infections per 10,000 Ommaya-days). 32% of infections occurred within 30 days of OmR placement. Most (74%) OmR infections occurring after 30 days post-placement were associated with OmR access in the preceding 30 days. Recovered organisms included coagulase-negative staphylococci (56%) and Propionibacterium acnes (24%). 70% of patients had fever and/or headache and 69% had cerebrospinal fluid pleocytosis. 50% of patients had the reservoir removed during treatment of the infection. CONCLUSIONS: OmR infection occurs in one of every 20 persons with the device. A third of the infections appear related to OmR placement while the remainder may occur at any time and usually are associated with recent reservoir access. Treatment often includes device removal.
Authors: David J Mauler; Kent R Richter; Sarah Merrill; Cristina Valencia-Sánchez; Chandan Krishna; Maciej M Mrugala Journal: Mol Clin Oncol Date: 2020-04-22
Authors: Fahed Zairi; Emilie Le Rhun; Nicolas Bertrand; Thomas Boulanger; Sophie Taillibert; Rabih Aboukais; Richard Assaker; Marc C Chamberlain Journal: J Neurooncol Date: 2015-06-13 Impact factor: 4.130
Authors: Andreas Peyrl; Monika Chocholous; Amedeo A Azizi; Thomas Czech; Christian Dorfer; Dieter Mitteregger; Johannes Gojo; Elke Minichmayr; Irene Slavc Journal: J Neurooncol Date: 2014-07-14 Impact factor: 4.130
Authors: Christoph Schwering; Gertrud Kammler; Eva Wibbeler; Martin Christner; Johannes K-M Knobloch; Miriam Nickel; Jonas Denecke; Michael Baehr; Angela Schulz Journal: J Child Neurol Date: 2021-02-05 Impact factor: 1.987